- Title
- Persistence of Detectable Anti-Pneumococcal Antibodies 4 Years After Pneumococcal Polysaccharide Vaccination in a Randomised Controlled Trial: The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE)
- Creator
- Attia, John; Horvat, Jay C.; Greenough, Robert; Abhayaratna, Walter P.; Newby, David; D'Este, Catherine; Tonkin, Andrew; Hopper, Ingrid; Levi, Christopher; Sturm, Jonathan; Durrheim, David; Hung, Joseph; Hunter, Tegan; McEvoy, Mark; Hopper, I; Levi, C; Sturm, J; Durrheim, D; Hung, J; Briffa, T; Chew, D; Anderson, P; Moon, L; Hansbro, Philip M.; McEvoy, M; Attia, J; Hure, Alexis; Peel, Roseanne; Ren, Shu; Dizon, Joshua; Chiu, Simon; Srikusalanukul, Wichat
- Relation
- NHMRC.1062563 http://purl.org/au-research/grants/nhmrc/1062563 & 1079187 http://purl.org/au-research/grants/nhmrc/1079187
- Relation
- Heart, Lung and Circulation Vol. 32, Issue 11, p. 1378-1385
- Publisher Link
- http://dx.doi.org/10.1016/j.hlc.2023.09.006
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2023
- Description
- Aim: Mouse models have indicated that the pneumococcal polysaccharide vaccine (PPV) can reduce atherosclerosis. This is probably through a process of molecular mimicry, where phosphorylcholine in the capsular polysaccharide of the vaccine elicits antibodies that cross-react with oxidised low-density lipoprotein and reduce plaque. We investigated whether a similar mechanism occurs in humans. Methods: A large national blinded, randomised, placebo-controlled trial of the PPV (Australian Study for the Prevention through Immunisation of Cardiovascular Events [AUSPICE]) is underway with fatal and nonfatal cardiovascular disease (CVD) events as the primary outcome. Participants at one centre agreed to a substudy measuring a number of biomarkers and surrogates of CVD over 4 years, including anti-pneumococcal antibodies (immunoglobulin G and immunoglobulin M), C-reactive protein, carotid intima-media thickness, pulse wave velocity, insulin, fasting blood glucose, glycated haemoglobin, and hepatorenal index. Results: Antipneumococcal immunoglobulin G and immunoglobulin M were both present and statistically significantly increased in the treated group compared to control at 4 years. However, there were no differences in any of the surrogate measures of CVD or metabolic markers at 4 years. Conclusions: While there were prolonged differences in anti-pneumococcal antibody titres following PPV vaccination, these did not appear to provide any cardioprotective effect, as measured by a range of markers. Final results using the fatal and nonfatal CVD events await the completion of national health record linkage next year. Trial Registration: ACTRN12615000536561.
- Subject
- anti-pneumococcal antibodies; pneumococcal polysaccharide vaccination; vaccination; molecular mimicry
- Identifier
- http://hdl.handle.net/1959.13/1498367
- Identifier
- uon:54542
- Identifier
- ISSN:1443-9506
- Language
- eng
- Reviewed
- Hits: 3669
- Visitors: 3539
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|